Investigation of the Effects of Curcumin on Serum Cytokines in Obese Individuals: A Randomized Controlled Trial

Abstract

Background. Obesity is a disorder often accompanied by a heightened state of systemic inflammation and immunoactivation. The present randomized crossover trial aimed to investigate the efficacy of curcumin, a bioactive polyphenol with established anti-inflammatory and immunomodulatory effects, on the serum levels of a panel of cytokines and mediators in obese individuals. Methods. Thirty obese individuals were randomized to receive curcumin at a daily dose of 1 g or a matched placebo for 4 weeks. Following a 2-week wash-out period, each group was assigned to the alternate treatment regimen for another 4 weeks. Serum samples were collected at the start and end of each study period. Serum levels of IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, IFNγ, EGF, MCP-1, and TNFα were measured using a multiplex Biochip Array Technology based method. Results. Mean serum IL-1β (P = 0.042), IL-4 (P = 0.008), and VEGF (P = 0.01) were found to be significantly reduced by curcumin therapy. In contrast, no significant difference was observed in the concentrations of IL-2, IL-6, IL-8, IL-10, IFNγ, EGF, and MCP-1. Conclusions. The findings of the present trial suggested that curcumin may exert immunomodulatory effects via altering the circulating concentrations of IL-1β, IL-4, and VEGF.

Curcumin attenuates severity of premenstrual syndrome symptoms: A randomized, double-blind, placebo-controlled trial

“…Literature review showed curcumin attracted increasing attention for the treatment of a range of conditions because of its numerous health benefits and people consuming curcumin in daily life have better health status [6,7,[36][37][38][39]. Due to side effects of chemical drugs, except in severe cases, chemical drugs consumption is not recommended for treating PMS.…”

Natural Nrf2 activators in diabetes

“…These compounds act as ROS scavengers, Nrf2 activators or both. Nrf2 activators have shown better results than direct antioxidants [123][124][125][126][127][128][129][130][131][132][133][134].…”

“…Curcumin has been assessed in the treatment of obesity [123,124], metabolic syndrome [125] and prediabetes [126]. Oral consumption is effective lowering serum triglyceride, interleukin-1 , interleukin-4, vascular endothelial growth factor, insulin resistance index (HOMA-IR) and increasing adiponectin.…”

Curcumin and insulin resistance—Molecular targets and clinical evidences

“…Later, an intervention was carried out with the same type and dose of curcumin in non‐diabetic obese individuals who had either at least two risk factors for coronary heart disease (CHD) (BMI > 30 and LDL: 160–190 mg/dL) or ≥ 2 CHD risk factors and LDL: 130–160 mg/dL. In this study, curcumin decreased IL‐1β, IL‐4, and the vascular endothelial grow factor (VEGF) in serum without changes in the interleukins IL‐1, IL‐2, IL‐6, IL‐8, IL‐10, the interferon gamma (IFNγ), epidermal growth factor (EGF), monocyte chemoattractant protein 1 (MCP‐1), and TNF‐α levels . It is important to note that these findings do not exclude a potential tissue‐specific anti‐inflammatory effect of curcumin.…”